Abstract
With the COVID-19 pandemic infecting millions of people, large-scale quarantine policies have been enacted across the globe. To assess the impact of quarantine measures on deaths, hospitalizations, and economic output, we expand the classical SEIR model to simulate the spread of COVID-19, incorporating effects of restrictive measures and segmenting the population based on health risk and economic vulnerability. For 76 weeks in a population of 330 million, we simulate a baseline scenario leaving current quarantine restrictions in place, rapidly reducing quarantine restrictions for non-seniors shortly after outbreak containment, and gradually relaxing quarantine restrictions for non-seniors. In the baseline scenario, there are 207,906 deaths and the economy shrinks by 34.0%. With a rapid relaxation, a second outbreak takes place, with 788,815 deaths, and the economy shrinks by 28.2%. With a gradual relaxation, there are 221,743 deaths, and the economy shrinks by 29.4%. Additionally, hospitalizations, deaths, and economic output are quite sensitive to disease spread by asymptomatic people. Strict restrictions on seniors with very gradual lifting of quarantine for non-seniors results in a limited number of deaths and lesser economic damage. Therefore, we recommend this strategy and measures that reduce non-quarantined disease spread to control the pandemic while making quarantine economically viable.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No specific funding was used for this work.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.